Comparable stake leader
Alison Mosca
SEC ownership of Clene Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001822791.
Disclosed value leader
Vivo Opportunity Fund Holdings, L.P.
Comparable rows
40/50
Latest evidence
13 Aug 2026
- Public ticker
- CLNN on Nasdaq
- Parsed ownership sources
-
3/4/5, 13D/G, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Alison Mosca
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
40 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Alison Mosca
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
13 Aug 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001822791
- Issuer location
- Salt Lake City, UT
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Clene Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Alison Mosca
Disclosed value leader
Vivo Opportunity Fund Hol...
Comparable rows
40/50
Latest evidence
13 Aug 2026
3/4/5
13D/G
13F
Lead comparable stake: 13%
10 rows are not safely comparable across share classes.
13D/G row: Alison Mosca
Showing 1-8 of 50 holder rows.
Quick read
Alison Mosca leads the comparable SEC ownership view at 13%.
40 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Alison Mosca's linked filing trail.
Comparable ownership
Top 5
Alison Mosca
13%
Vivo Opportunity Fund Holdings, L.P.
10%
Empery Asset Management, LP
7.2%
4LIFE RESEARCH LLC
6.5%
ARMISTICE CAPITAL, LLC
5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Alison Mosca |
3/4/5
13D/G
Director
|
13%
from 13D/G
|
$3,005,527
710,326 shares
mixed-class rows
|
— | 13 Aug 2026 |
| Vivo Opportunity Fund Holdings, L.P. |
13D/G
|
10%
|
$8,445,503
1,321,675 shares
|
$0 | 30 Jun 2026 |
| Empery Asset Management, LP |
13D/G
13F
Company
|
7.2%
|
$5,856,639
916,532 shares
|
$0 | 30 Jun 2026 |
| 4LIFE RESEARCH LLC |
13D/G
David Lisonbee
|
6.5%
|
$84,921
555,328 shares
|
$0 | 20 Dec 2024 |
| ARMISTICE CAPITAL, LLC |
13D/G
|
5%
|
$1,257,303
419,101 shares
|
$0 | 31 Dec 2024 |
| AWM Investment Company, Inc. |
13D/G
|
4.7%
|
$3,012,500
500,000 shares
|
$0 | 30 Sep 2025 |
| General Resonance LLC |
3/4/5
10%+ Owner
|
5.3%
|
$3,762,515
704,591 shares
|
— | 21 Aug 2025 |
| Chidozie Ugwumba |
3/4/5
10%+ Owner
|
0.78%
|
$641,185
103,417 shares
|
-$5,781,161 | 17 Jul 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$5,564,496.
Buys
$216,664
Insiders: 1
Sells
$5,781,161
Insiders: 1
Net
-$5,564,496
Shares: -938,489
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 33,333
Shares: 971,822
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 446,583 | $0 | $2,636,999 | -$2,636,999 |
| 6-9 | 33,333 | 525,239 | $216,664 | $3,144,162 | -$2,927,498 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-17 of 17 reporting-owner rows connected to Clene Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
17
Largest Forms 3/4/5 holder
General Resonance LLC
Net 12M change
-$5,564,496
Latest report
13 Aug 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| General Resonance LLC | 10%+ Owner | $3,762,515 | Filing P/S | 21 Aug 2025 | ||
| David J. Matlin | Director | $3,105,856 | +$216,665 | +7.5% | Filing P/S | 13 Aug 2026 |
| Alison Mosca | Director | $3,005,527 | Mixed | 13 Aug 2026 | ||
| Chidozie Ugwumba | 10%+ Owner | $641,185 | -$5,781,161 | -90% | Filing P/S | 17 Jul 2026 |
| Morgan R. Brown | Chief Financial Officer | $53,800 | Mixed | 11 Jun 2026 | ||
| Robert Glanzman | Chief Medical Officer | $4,331 | Mixed | 16 May 2022 | ||
| Mark Mortenson | Chief Science Officer | Mixed | 11 Jun 2026 | |||
| Reed N. Wilcox | Director | Mixed | 13 Aug 2026 | |||
| Robert Dee Etherington | President & CEO, Director | Mixed | 11 Jun 2026 | |||
| Shalom Jacobovitz | Director | Mixed | 13 Aug 2026 | |||
| Arjun Jj Desai | Director | Mixed | 13 Aug 2026 | |||
| Matthew Kiernan | Director | Mixed | 13 Aug 2026 | |||
| Fiona Costello | Director | Mixed | 18 May 2021 | |||
| Jonathon Gay | Director | Mixed | 13 Aug 2026 | |||
| Tae Heum Jeong | Chief Finance Officer | Mixed | 04 Nov 2021 | |||
| Vallerie McLaughlin | Director | Mixed | 13 Aug 2026 | |||
| John Henry Stevens | Director | Mixed | 18 Sep 2023 |
Recent insider transactions for Clene Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Matthew Kiernan | CLNN | stock option | Award | 3,195 | 3,195 | 13 Aug 2026 | Direct | |||
| Arjun Jj Desai | CLNN | stock option | Award | 3,674 | 3,674 | 13 Aug 2026 | Direct | |||
| Alison Mosca | CLNN | stock option | Award | 4,872 | 4,872 | 13 Aug 2026 | Direct | |||
| Shalom Jacobovitz | CLNN | stock option | Award | 4,752 | 4,752 | 13 Aug 2026 | Direct | |||
| Jonathon Gay | CLNN | stock option | Award | 3,794 | 3,794 | 13 Aug 2026 | Direct | |||
| Vallerie McLaughlin | CLNN | stock option | Award | 3,514 | 3,514 | 13 Aug 2026 | Direct | |||
| Reed N. Wilcox | CLNN | stock option | Award | 3,514 | 3,514 | 13 Aug 2026 | Direct | |||
| David J. Matlin | CLNN | stock option | Award | 6,230 | 6,230 | 13 Aug 2026 | Direct | |||
| Chidozie Ugwumba | CLNN | Common Stock Purchase Warrant ($4.82 strike) | Other | -100% | -424,358 | 0 | 17 Jul 2026 | By SymBiosis II LLC | ||
| Chidozie Ugwumba | CLNN | Warrant to Purchase Common Stock (Tranche B, $30.00 strike) | Other | -100% | -375,000 | 0 | 17 Jul 2026 | By SymBiosis II LLC | ||
| Mark Mortenson | CLNN | stock option | Award | 45,000 | 45,000 | 11 Jun 2026 | Direct | |||
| Robert Dee Etherington | CLNN | stock option | Award | 65,000 | 65,000 | 11 Jun 2026 | Direct | |||
| Morgan R. Brown | CLNN | stock option | Award | 15,000 | 15,000 | 11 Jun 2026 | Direct | |||
| Vallerie McLaughlin | CLNN | stock option | Award | 3,564 | 2,064 | 21 May 2026 | Direct | |||
| Arjun Jj Desai | CLNN | stock option | Award | 3,658 | 2,158 | 21 May 2026 | Direct | |||
| Alison Mosca | CLNN | stock option | Award | 4,361 | 2,861 | 21 May 2026 | Direct | |||
| David J. Matlin | CLNN | stock option | Award | 5,159 | 3,659 | 21 May 2026 | Direct | |||
| Shalom Jacobovitz | CLNN | stock option | Award | 4,291 | 2,791 | 21 May 2026 | Direct | |||
| Matthew Kiernan | CLNN | stock option | Award | 3,376 | 1,876 | 21 May 2026 | Direct | |||
| Jonathon Gay | CLNN | stock option | Award | 3,728 | 2,228 | 21 May 2026 | Direct | |||
| Reed N. Wilcox | CLNN | stock option | Award | 3,564 | 2,064 | 21 May 2026 | Direct | |||
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -41.5% | $454,435 | $6.20 | -73,296 | 103,417 | 12 May 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -11.2% | $149,695 | $6.75 | -22,177 | 176,713 | 11 May 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -26.8% | $495,611 | $6.80 | -72,884 | 198,890 | 04 May 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -2.09% | $34,828 | $6.01 | -5,795 | 271,774 | 01 May 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -2.02% | $34,875 | $6.08 | -5,736 | 277,569 | 30 Apr 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -4.12% | $68,517 | $5.63 | -12,170 | 283,305 | 29 Apr 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -0.54% | $9,387 | $5.90 | -1,591 | 295,475 | 28 Apr 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -17.1% | $376,658 | $6.14 | -61,345 | 297,066 | 21 Apr 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -1.19% | $26,426 | $6.12 | -4,318 | 358,411 | 20 Apr 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -6.46% | $161,007 | $6.43 | -25,040 | 362,729 | 17 Apr 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -1.96% | $49,587 | $6.40 | -7,748 | 387,769 | 16 Apr 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -1.59% | $41,304 | $6.48 | -6,374 | 395,517 | 15 Apr 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -5.84% | $119,889 | $4.81 | -24,925 | 401,891 | 02 Apr 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -0.99% | $21,262 | $4.97 | -4,278 | 426,816 | 01 Apr 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -13.6% | $331,796 | $4.88 | -67,991 | 431,094 | 31 Mar 2026 | By Symbiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -3.02% | $79,234 | $5.10 | -15,536 | 499,085 | 30 Mar 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -3.28% | $82,982 | $4.75 | -17,470 | 514,621 | 27 Mar 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -0.99% | $28,723 | $5.40 | -5,319 | 532,091 | 26 Mar 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -1.3% | $39,039 | $5.50 | -7,098 | 537,410 | 25 Mar 2026 | By SymBiosis II, LLC |
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -1% | $31,744 | $5.78 | -5,492 | 544,508 | 24 Mar 2026 | By SymBiosis II, LLC |
| Vallerie McLaughlin | CLNN | stock option | Award | 3,030 | 3,030 | 19 Feb 2026 | Direct | |||
| Reed N. Wilcox | CLNN | stock option | Award | 3,306 | 3,306 | 19 Feb 2026 | Direct | |||
| Alison Mosca | CLNN | stock option | Award | 4,201 | 4,201 | 19 Feb 2026 | Direct | |||
| David J. Matlin | CLNN | stock option | Award | 5,372 | 5,372 | 19 Feb 2026 | Direct | |||
| Arjun Jj Desai | CLNN | stock option | Award | 3,168 | 3,168 | 19 Feb 2026 | Direct | |||
| Shalom Jacobovitz | CLNN | stock option | Award | 4,098 | 4,098 | 19 Feb 2026 | Direct | |||
| Jonathon Gay | CLNN | stock option | Award | 3,271 | 3,271 | 19 Feb 2026 | Direct | |||
| Matthew Kiernan | CLNN | stock option | Award | 2,755 | 2,755 | 19 Feb 2026 | Direct | |||
| Chidozie Ugwumba | CLNN | Common Stock | Sale | -1% | $22,792 | $4.10 | -5,559 | 550,000 | 03 Feb 2026 | By Symbiosis II, LLC |
* marks a reported price that did not pass the local price check.